Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Chawla, Bharat
and
Luxton‐Andrew, Heather
2008.
Long‐term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open‐label, prospective trial.
Human Psychopharmacology: Clinical and Experimental,
Vol. 23,
Issue. 3,
p.
211.
San, Luis
Casillas, Marta
Ciudad, Antonio
and
Gilaberte, Inmaculada
2008.
Olanzapine Orally Disintegrating Tablet: A Review of Efficacy and Compliance.
CNS Neuroscience & Therapeutics,
Vol. 14,
Issue. 3,
p.
203.
Karagianis, Jamie
Hoffmann, Vicki Poole
Arranz, Belen
Treuer, Tamás
Maguire, Gerald A.
de Haan, Lieuwe
and
Chawla, Bharat
2008.
Orally disintegrating olanzapine and potential differences in treatment‐emergent weight gain.
Human Psychopharmacology: Clinical and Experimental,
Vol. 23,
Issue. 4,
p.
275.
2008.
Current awareness: Pharmacoepidemiology and drug safety.
Pharmacoepidemiology and Drug Safety,
Vol. 17,
Issue. 6,
Karagianis, J.
Grossman, L.
Landry, J.
Reed, V.A.
de Haan, L.
Maguire, G.A.
Hoffmann, V.P.
and
Milev, R.
2009.
A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: The PLATYPUS Study.
Schizophrenia Research,
Vol. 113,
Issue. 1,
p.
41.
Hoffmann, Vicki Poole
Case, Michael
Jacobson, Jennie G.
and
Francis, Jennie Lin
2009.
Listing of metabolic changes in healthy volunteers receiving orally dissolving olanzapine or oral olanzapine: Data from a clinical study that was terminated early.
Schizophrenia Research,
Vol. 115,
Issue. 2-3,
p.
370.
Holt, Richard I. G.
and
Peveler, Robert C.
2009.
Obesity, serious mental illness and antipsychotic drugs.
Diabetes, Obesity and Metabolism,
Vol. 11,
Issue. 7,
p.
665.
Karagianis, J.
Landry, J.
Hoffmann, V. P.
Grossman, L.
De Haan, L.
Maguire, G.
Milev, R.
and
Holt, S.
2010.
An exploratory analysis of factors associated with weight change in a 16-week trial of oral vs. orally disintegrating olanzapine: the PLATYPUS study.
International Journal of Clinical Practice,
Vol. 64,
Issue. 11,
p.
1520.
Vidarsdottir, Solrun
Roelfsema, Ferdinand
Streefland, Trea
Holst, Jens J
Rehfeld, Jens F
and
Pijl, Hanno
2010.
Short-term treatment with olanzapine does not modulate gut hormone secretion: olanzapine disintegrating versus standard tablets.
European Journal of Endocrinology,
Vol. 162,
Issue. 1,
p.
75.
Kusumi, Ichiro
Honda, Minoru
Uemura, Keiichi
Sugawara, Yasuhumi
Kohsaka, Masako
Tochigi, Akihiko
and
Koyama, Tsukasa
2012.
Effect of olanzapine orally disintegrating tablet versus oral standard tablet on body weight in patients with schizophrenia: a randomized open-label trial.
Progress in Neuro-Psychopharmacology and Biological Psychiatry,
Vol. 36,
Issue. 2,
p.
313.
Caccia, Silvio
2013.
Safety and Pharmacokinetics of Atypical Antipsychotics in Children and Adolescents.
Pediatric Drugs,
Vol. 15,
Issue. 3,
p.
217.
Martínez-Ortega, José María
Funes-Godoy, Silvia
Díaz-Atienza, Francisco
Gutiérrez-Rojas, Luis
Pérez-Costillas, Lucía
and
Gurpegui, Manuel
2013.
Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review.
European Child & Adolescent Psychiatry,
Vol. 22,
Issue. 8,
p.
457.
Pillay, Jennifer
Boylan, Khrista
Newton, Amanda
Hartling, Lisa
Vandermeer, Ben
Nuspl, Megan
MacGregor, Tara
Featherstone, Robin
and
Carrey, Normand
2018.
Harms of Antipsychotics in Children and Young Adults: A Systematic Review Update.
The Canadian Journal of Psychiatry,
Vol. 63,
Issue. 10,
p.
661.
Shymko, Gordon
Dobson, Louise
Acacio, Maria Cynthia
Grace, Terina
Tadier, Sarah
and
Waters, Flavie
2023.
Weight changes in people with early psychosis treated with oral or long-acting injectable aripiprazole.
Schizophrenia Research,
Vol. 251,
Issue. ,
p.
74.
Comments
No Comments have been published for this article.